Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer
Status: COMPLETED
Study type: OBSERVATIONAL
Conditions: Breast Cancer
Interventions: DRUG: Everolimus and exemestane
Sponsor: Novartis Healthcare A/S